Effect of intravenous immunoglobulin in Lambert-Eaton myasthenic syndrome with small-cell lung cancer: correlation with the titer of anti-voltage-gated calcium channel antibody.
Takano
H
H
Department of Neurology, Niigata University, Japan.
Tanaka
M
M
Koike
R
R
Nagai
H
H
Arakawa
M
M
Tsuji
S
S
D000200:Action Potentials; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D015220:Calcium Channels / Q000276:immunology*; D018288:Carcinoma, Small Cell / Q000150:complications* / Q000503:physiopathology / Q000628:therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood*; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D015624:Lambert-Eaton Myasthenic Syndrome / Q000150:complications / Q000503:physiopathology / Q000628:therapy*; D008175:Lung Neoplasms / Q000150:complications* / Q000503:physiopathology / Q000628:therapy; D008297:Male; D009132:Muscles / Q000503:physiopathology*; D010956:Plasmapheresis
D015220:Calcium Channels; D007074:Immunoglobulin G; D016756:Immunoglobulins, Intravenous; D005047:Etoposide; D003520:Cyclophosphamide